Creative Biolabs Releases Replication-Competent Virus Testing Service

January 28 19:32 2019
New York, US–Jan 28, 2019 Creative Biolabs, a CRO specializing in antibody discovery and immune cell based therapy, now releases a replication-competent virus testing service for gene-mediated cell therapy and viral vector-based gene therapy programs, intending to help global customers move the viral vector-based therapy into the clinic more quickly.

New York, US–Jan 28, 2019  Creative Biolabs, a CRO specializing in antibody discovery and immune cell based therapy, now releases a replication-competent virus testing service for gene-mediated cell therapy and viral vector-based gene therapy programs, intending to help global customers move the viral vector-based therapy into the clinic more quickly.

 

Compared to the traditional methods, such as invasive surgeries, radiation and chemotherapy, chimeric antigen receptor (CAR)-engineered T cell therapy is characterized by higher specificity and less toxicity, which has become the most promising immunotherapy and has shown remarkable ability to eliminate various kinds of tumors.

 

“Despite the wide application and powerful usage of viral vectors in gene therapies and gene-mediated cell therapies for a variety of inherited and acquired diseases, it is challenging to move any viral vector into the clinic due to the limits from the presence of replication-competent lentivirus (RCL) or replication-competent retrovirus (RCR). Therefore, during the various stages of vector preparation and ex vivo patient treatment, replication-competent virus (RCV) testing plays an essential role to test viruses which may have been produced through recombination. Meanwhile, assay development for RCL/RCR is also particularly challenging.” said a scientist from Creative Biolabs.

 

“We fully understand the needs and importance. Based on the advanced GLP/GMP testing platform, our Ph.D. level scientists and skillful technicians can provide a high-quality replication-competent virus testing service and effectively perform the RCL/RCR testing abiding by the FDA guidance, ensuring patients are not inadvertently exposed to replicating virus.”

 

With years of experience, Creative Biolabs has established several world-leading platforms to serve worldwide clients with academic or clinical requirements. Besides replication-competent virus testing services, Creative Biolabs can deliver a wide range of CAR T immunotherapy services that are tailored to clients’ individual requirements in terms of science, timelines, and cost. For more information, please visit https://www.creative-biolabs.com/car-t/.

 

About Creative Biolabs

As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/car-t/